|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Hyponatremia in cirrhosis:Pathophysiology and management显示文摘Hyponatremia is frequently seen in patients with ascites secondary to advanced cirrhosis and portal hypertension.The development of ascites in patients with cirrhosis is multi-factorial.Portal hypertension and the associated systemic vasodilation lead to activation of the sodium-retaining neurohumoral mechanisms which include the renin-angiotensin-aldosterone system,sympathetic nervous system and antidiuretic hormone(ADH).The net effect is the avid retention of sodium and water to compensate for the low effective circulatory volume resulting in the development of ascites.Although not apparent in the early stages of cirrhosis,the progression of cirrhosis and ascites leads to impairment of the kidneys to eliminate solutefree water.This leads to additional compensatory mechanisms including non-osmotic secretion of ADH,also known as arginine vasopressin,further worsening excess water retention and thereby hyponatremia.Hyponatremia is associated with increased morbidity and mortality in patients with cirrhosis,and is an important prognostic marker both before and after liver transplant.The management of hyponatremia in this setting is a challenge as conventional therapy for hyponatremia including fluid restriction and loop diuretics are frequently inefficacious.In this review,we discuss the pathophysiology and various treatment modalities,including selective vasopressin receptor antagonists,for the management of hyponatremia in patients with cirrhosis. | Savio John Paul J Thuluvath | 2015 | World Journal of Gastroenterology2015，21，11： | 15 |
| 2 | Hepatorenal syndrome显示文摘Hepatorenal syndrome (HRS) is a 'functional' and reversible form of renal failure that occurs in patients with advanced chronic liver disease. The distinctive hallmark feature of HRS is the intense renal vasoconstriction caused by interactions between systemic and portal hemodynamics. This results in activation of vasoconstrictors and suppression of vasodilators in the renal circulation. Epidemiology, pathophysiology, as well as current and emerging therapies of HRS are discussed in this review. | Sharon Turban Paul J Thuluvath Mohamed G Atta | 2007 | World Journal of Gastroenterology2007，13，30： | 14 |
| 3 | Outcomes of patients with cirrhosis undergoing non-hepatic surgery:Risk assessment and management显示文摘The reported mortality rates in patients with cirrhosis undergoing various non-transplant surgical procedures range from 8.3% to 25%. This wide range of mortality rates is related to severity of liver disease, type of surgery, demographics of patient population, expertise of the surgical, anesthesia and intensive care unit team and finally, reporting bias. In this article, we will review the pathophysiology, morbidity and mortality associated with non-hepatic surgery in patients with cirrhosis, and then recommend an algorithm for risk assessment and evidence based management strategy to optimize post-surgical outcomes. | Farida Millwala Geoffrey C Nguyen Paul J Thuluvath | 2007 | World Journal of Gastroenterology2007，13，30： | 10 |
| 4 | Non-alcoholic fatty liver and chronic kidney disease:Retrospect,introspect,and prospect显示文摘With the growing prevalence of obesity and diabetes in the United States and across the world,a rise in the overall incidence and prevalence of non-alcoholic fatty liver disease(NAFLD)is expected.The risk factors for NAFLD are also associated with the development of chronic kidney disease(CKD).We review the epidemiology,risk factors,genetics,implications of gut dysbiosis,and specific pathogenic mechanisms linking NAFLD to CKD.Mechanisms such as ectopic lipid accumulation,cellular signaling abnormalities,and the interplay between fructose consumption and uric acid accumulation have led to the emergence of potential therapeutic implications for this patient population.Transplant evaluation in the setting of both NAFLD and CKD is also reviewed.Potential strategies for surveillance and management include the monitoring of comorbidities,the use of non-invasive fibrosis scoring systems,and the measurement of laboratory markers.Lastly,we discuss the management of patients with NAFLD and CKD,from preventative measures to experimental interventions. | Rajiv Heda Masahiko Yazawa Michelle Shi Madhu Bhaskaran Fuad Zain Aloor Paul J Thuluvath Sanjaya K Satapathy | 2021 | World Journal of Gastroenterology2021，27，17： | 3 |
| 5 | Biliary Complications after Liver Transplantation: the Role of Endoscopy显示文摘 | P. Thuluvath P. Pfau M. Kimmey G. Ginsberg | 2005 | Endoscopy2005，，09： | 3 |
| 6 | Endoscopic suturing closure of large mucosal defects after endoscopic submucosal dissection is technically feasible, fast, and eliminates the need for hospitalization (with videos)显示文摘 | Sergey V. Kantsevoy Marianne Bitner Aleksandr A. Mitrakov Paul J. Thuluvath | 2013 | Gastrointestinal Endoscopy2013，，： | 3 |
| 7 | Liver injury in COVID-19:The hepatic aspect of the respiratory syndrome-what we know so far显示文摘The 2019 novel coronavirus disease(COVID-19)pandemic due to severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)has posed a serious threat to global public health.Although primarily,the infection causes lung injury,liver enzyme abnormalities have also been reported to occur during the course of the disease.We conducted an extensive literature review using the PubMed database on articles covering a broad range of issues related to COVID-19 and hepatic injury.The present review summarizes available information on the spectrum of liver involvement,the possible mechanisms and risk factors of liver injury due to SARS-CoV-2 infection,and the prognostic significance of the presence of liver injury.Hopefully,this review will enable clinicians,especially the hepatologists,to understand and manage the liver derangements they may encounter in these patients better and provide guidance for further studies on the liver injury of COVID-19. | Prajna Anirvan Pankaj Bharali Mrinal Gogoi Paul J Thuluvath Shivaram P Singh Sanjaya K Satapathy | 2020 | World Journal of Hepatology2020，12，12： | 2 |
| 8 | Impact of HCV and hepatic encephalopathy on the outcome of patients admitted with alcoholic hepatitis显示文摘 | THULUVATH PJ NGUYEN GC | 2010 | Hepatology2010，52，： | 1 |
| 9 | Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States 显示文摘 | Nair S Verma S Thuluvath PJ | 2002 | Hepatology2002，35，1： | 1 |
| 10 | Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma显示文摘 | Koopmann J Thuluvath PJ Zahurak ML | 2004 | Cancer2004，101，7： | 1 |
| 11 | Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis:a casecontrol study显示文摘 | Poonawala A Naif SP Thuluvath PJ | 2000 | Hepatology2000，32，41： | 1 |
| 12 | Portal hypertensive gastropathy显示文摘 | Paul J Thuluvath Hwan Y Yoo | 2002 | The American Journal of Gastroenterology2002，，12： | 1 |
| 13 | Racial disparity in liver disease:Biological,cultural,or socioeconomic factors显示文摘 | Nguyen GC Thuluvath PJ | 2008 | Hepatology2008，47，3： | 1 |
| 14 | Screening for Hepatocellular Carcinoma显示文摘 | Ayman Koteish Paul J. Thuluvath | 2002 | Journal of Vascular and Interventional Radiology2002，，9： | 1 |
| 15 | Portal Hypertensive gastropathy显示文摘 | Thuluvath PJ Yoo HY | 2002 | Am J Gastroenterol2002，97，12： | 1 |
| 16 | Liver transplantation in the United States, 1999-2008 显示文摘 | Thuluvath P J Guidinger MK Fung J J | 2010 | Am J Transplant2010，10，42： | 1 |
| 17 | Autonomic neuropathy in chronic liver disease显示文摘 | THULUVATH PJ TRIGER DR | 1998 | Qjmed1998，72，： | 1 |
| 18 | An endoscopic approach tobiliary complications following orthotopic liver transplantation 显示文摘 | Thuluvath PJ Atassi T Lee J | 2003 | Livet Int2003，23，3： | 1 |
| 19 | Autonomicdysfunction and cholelithiasis in patients with cirrhosis 显示文摘 | CHAWLA A PUTHUMANA L THULUVATH PJ | 2001 | Dig Dis Sci2001，46，3： | 1 |
| 20 | Graft and patient survival after adult live donor liver transplantation compared to a matched cohort who received a deceased donor transplantation 显示文摘 | Thuluvath PJ Yoo HY | 2004 | Liver Transpl2004，10，10： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员